Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN )

9.870 -0.240 (-2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Earnings Preview: UroGen Pharma
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
UroGen Pharma Announces Upcoming 2021 Conferences
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
From UroGen Pharma Ltd.
Via Business Wire
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows. Areas of Interest: The largest company by market cap to set a new 52-week low was Alibaba Group Holding (... 
Via Benzinga
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
From UroGen Pharma Ltd.
Via Business Wire
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
From UroGen Pharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 16 companies achieved new lows for the year. Points of Interest: The largest company in terms of market cap to set a new 52-week low was Tencent... 
Via Benzinga
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
From UroGen Pharma Ltd
Via Business Wire
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces June 2021 Conference Schedule
From UroGen Pharma Ltd.
Via Business Wire
Looking Into UroGen Pharma's Return On Capital Employed
UroGen Pharma (NASDAQ:URGN) reported Q1 sales of $7.49 million. Earnings fell to a loss of $26.11 million, resulting in a 4.18% decrease from last quarter. In Q4, UroGen Pharma... 
Via Benzinga
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52. Repro Med Systems, Inc... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.